Sharemaestro Newsreel

Replimune Group (NASDAQ:REPL) Releases Quarterly Earnings Results

Replimune Group (NASDAQ:REPL) reported a Q1 loss of $0.72 per share, missing analyst estimates. Despite the earnings miss and ongoing litigation, the company's shares fell by 1.4% to $14.97, and it expects to launch TUDRIQEV™ (RP1) for advanced melanoma within 60 days following FDA …

Altimmune (ALT) President and CEO Jerome Durso Buys 15,000 Shares

Altimmune Inc.'s President and CEO, Jerome Durso, recently purchased 15,000 shares of the company's stock, increasing his direct ownership to 62,500 shares. This transaction is part of a larger trend of insider buying at Altimmune, with 11 insider buys and no sells in the …

Dare Bioscience earnings beat by $0.11, revenue topped estimates

Dare Bioscience (NASDAQ: DARE) reported Q2 EPS of $-0.2000, surpassing analyst estimates by $0.11, and revenue of $187.55K, significantly beating the consensus estimate of $1.67K. Despite the positive earnings surprise, the company's stock has seen a decline of -36.87% over the last three months …

Fortress Biotech earnings beat by $0.11, revenue fell short of estimates

Septerna (NASDAQ:SEPN) COO Elizabeth Bhatt Sells 25,000 Shares of Stock

Top Kailera Therapeutics (KLRA) Competitors 2026

Verastem (VSTM) Q2 2026 Earnings Call Transcript

Verastem (VSTM) reported strong Q2 2026 results, with net product revenue of $25.1 million and total revenue of $40.1 million. The company secured $75 million in non-dilutive royalty financing and a $15 million milestone payment, extending its cash runway into the second half of …

Septerna president & COO Elizabeth Bhatt disposes of $1.1m in stock

Elizabeth Bhatt, President and COO of Septerna, Inc. (NASDAQ:SEPN), sold 25,000 shares of common stock for $1.1 million on August 11, 2026, after acquiring them through stock option exercises. These transactions were executed under a Rule 10b5-1 sales plan, leaving Bhatt with 174,209 directly …

LB PHARMACEUTICALS INC : LEERINK PARTNERS RAISES TARGET PRICE TO $55 FROM $40

Leerink Partners has increased its target price for LB PHARMACEUTICALS INC from $40 to $55. This adjustment indicates a more optimistic outlook by the firm on the pharmaceutical company's future performance.

Tempest Therapeutics Q2 loss narrows to $5.2m; advances CAR-T pipeline

Tempest Therapeutics reported a Q2 2026 net loss of $5.2 million, a significant narrowing from the previous year, primarily due to reduced R&D expenses. However, year-to-date losses widened to $32.9 million, influenced by a $22.1 million charge for acquired in-process R&D. The company is …

REPL SHAREHOLDER ALERT: Securities Fraud Lawsuit Filed on

Kirby McInerney LLP has filed a securities fraud class action lawsuit against Replimune Group, Inc. (NASDAQ: REPL) on behalf of investors who purchased securities between October 20, 2025, and April 10, 2026. The lawsuit alleges that Replimune made misleading statements regarding the Biologics License …

Jade Biosciences (JBIO) Shares Just Moved, So What Is Going On?

Jade Biosciences (JBIO) recently released its Q2 2026 results, reporting a net loss of $55.77 million. Despite strong year-to-date share price returns of 63.91% and a 1-year total shareholder return of 216.64%, the stock's 90-day return declined, and it trades well below the average …

H.C. Wainwright Maintains Jade Biosciences(JBIO.US) With Buy Rating, Maintains Target Price $55

H.C. Wainwright has reiterated its Buy rating for Jade Biosciences (JBIO.US), keeping the target price at $55. This indicates continued confidence in the company's performance and future prospects from the analyst firm.

CURIS INC SEC Filing (Aug 13, 2026)

This article reports on a CURIS INC SEC Filing dated August 13, 2026, which is a Notice of Effectiveness for Form S-1, with an effectiveness date of August 12, 2026, at 5:30 P.M. The filing has a neutral impact and sentiment according to AI-generated …

ImmuCell (NASDAQ:ICCC) Announces Earnings Results, Beats Estimates By $0.15 EPS

ImmuCell (NASDAQ:ICCC) reported its earnings results, beating the consensus estimate by $0.15 EPS with reported earnings of $0.20 per share. The biotechnology company also surpassed revenue expectations, bringing in $7.19 million against an anticipated $5.40 million. Despite these positive financial results, the company maintains …

AXSM|Axsome Therapeutics Inc|Price:213.630|Chg%:-1.030

Incyte Corporation (INCY) has the Bigger Revenue Base, but Could Halozyme Therapeutics, Inc. (HALO) have the Better Economics?

On July 20, Halozyme Therapeutics, Inc. (NASDAQ:HALO) and Incyte Corporation (NASDAQ:INCY) announced a global collaboration and licensing deal to develop a subcutaneous formulation of Incyte's INCA033989. The first-in-class monoclonal antibody targets mutant calreticulin (mutCALR)-expressing myeloproliferative neoplasms. By utilizing Halozyme's proprietary ENHANZE drug delivery technology, …

Could Arcus Biosciences (RCUS) and Summit Therapeutics (SMMT)’s Cancer Drug Partnership Create a New Treatment Standard?

On July 22, Arcus Biosciences, Inc. (NYSE:RCUS) and Summit Therapeutics Inc. (NASDAQ:SMMT) announced a major clinical trial collaboration to combine Arcus's casdatifan (an investigational HIF-2α inhibitor) with Summit's ivonescimab (an investigational PD-1/VEGF bispecific antibody). The study aims to evaluate the safety and efficacy of …

Fortress Biotech (NASDAQ:FBIO) Posts Earnings Results, Beats Estimates By $0.12 EPS

Fortress Biotech (NASDAQ:FBIO) announced its quarterly earnings, reporting an adjusted loss of $0.08 per share, surpassing the consensus estimate by $0.12. The biopharmaceutical company also exceeded revenue forecasts with $18.72 million. Despite mixed analyst sentiment and a "Hold" consensus rating, institutional investors own a …

Cibus (NASDAQ:CBUS) Releases Earnings Results

ADCT|ADC Therapeutics SA|Price:1.050|Chg%:-0.180

Kura Oncology (KURA) Stock Revenue Growth Clashes With Mounting Losses

Arcus Biosciences (RCUS) Reported Q2 2026 Results, Is The Stock A Bargain?

Arcus Biosciences reported Q2 2026 results with $41 million in revenue and a $91 million net loss, along with new full-year revenue guidance. The stock has seen significant price returns (16.07% in 90 days, 24.35% YTD), and a current valuation suggests it is 24% …

Cellectar Biosciences Releases Q2 2026 Financial Results

Cellectar Biosciences (CLRB) reported a wider-than-expected loss of $0.57 per share for Q2 2026, missing analyst estimates by 9.6%, with a net loss of $6.9M. Despite this, the company showed significant year-over-year improvement, with the per-share loss narrowing by 83.2% from $3.39 in the …

TD Cowen Maintains Century Therapeutics(IPSC.US) With Buy Rating

TD Cowen has reiterated its Buy rating on Century Therapeutics (IPSC.US). This indicates a continued positive outlook from the firm regarding the company's stock performance.

Denali Therapeutics (NASDAQ:DNLI) Insider Sells $71,624.99 in Stock

Denali Therapeutics (NASDAQ:DNLI) insider Alexander Schuth sold 2,857 shares of the company's stock for approximately $71,625, reducing his position by 1% while still holding over 281,000 shares. Despite the company missing analysts' EPS estimates with a quarterly loss of $0.68 per share, revenue exceeded …

Stifel Maintains UniQure NV(QURE.US) With Buy Rating, Maintains Target Price $71

Stifel has reiterated its Buy rating for UniQure NV (QURE.US), maintaining its target price at $71. This indicates continued confidence from Stifel in the company's stock performance.

Caribou Biosciences (NASDAQ:CRBU) Releases Earnings Results, Beats Expectations By $0.08 EPS

Caribou Biosciences (NASDAQ:CRBU) reported a quarterly loss of $0.24 per share, surpassing analyst expectations by $0.08, though revenue of $1.50 million fell short of estimates. Following the announcement, shares declined by 5.3% to $1.61. Despite substantial losses and a negative net margin, institutional investors …

Barclays PLC (ZNTL) discloses 2.26M-share, 3.17% stake in Zentalis

Barclays PLC has filed an amended Schedule 13G, disclosing a 3.17% beneficial ownership stake in Zentalis Pharmaceuticals Inc. (ZNTL), totaling 2,263,328 shares as of June 30, 2026. This filing indicates that Barclays now holds 5 percent or less of the class. The ownership includes …

Akari Therapeutics Q2 Results: Net loss widens to $4.8 million

Akari Therapeutics reported a net loss of $4.8 million for Q2 2026, widening from $1.9 million year-over-year, primarily due to increased R&D expenses as it advances its lead ADC candidate, AKTX-101, towards mid-2027 Phase 1 trials. The company strengthened its financial position by raising …

Could AbbVie Inc. (ABBV) Win as Genmab A/S (GMAB) Faces a New Regulatory Test for Epcoritamab?

On July 23, Genmab A/S (NASDAQ:GMAB) and AbbVie Inc. (NYSE:ABBV) clarified a key clinical setback regarding their jointly developed T-cell engaging bispecific antibody, epcoritamab (DuoBody-CD3xCD20). The Phase 3 EPCORE DLBCL-1 study evaluated epcoritamab monotherapy against investigator's choice of chemoimmunotherapy in transplant-ineligible adults with relapsed/refractory …

DRTS Forecast — Price Target — Prediction for 2027

Stocks See Support from Favorable PPI Report

The S&P 500 Index ($SPX) (SPY) is up +0.57%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +0.04%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +1.22%. September E-mini S&P futures (ESU26) are up +0.58%, and September E-mini Nasdaq futures (NQU26) are …

Omeros (OMER) Stock Jumps On YARTEMLEA Profit Breakthrough

Quantinuum (QNTM) Stock Wrestles With IPO Charge After Revenue Jump

Alpha Cognition (NASDAQ:ACOG) Announces Quarterly Earnings Results